|4Nov 30, 2:54 PM ET

Friedland Jeffrey 4

4 · Intiva BioPharma Inc. · Filed Nov 30, 2017

Insider Transaction Report

Form 4
Period: 2017-11-29
Friedland Jeffrey
DirectorChief Executive Officer10% Owner
Transactions
  • Other

    Common Stock

    2017-11-29+130,859208,000 total(indirect: By LLC)
  • Other

    Class C Warrants (right to buy)

    2017-11-29+20,80020,800 total(indirect: By LLC)
    Exercise: $0.50From: 2017-11-29Exp: 2018-07-14Common Stock (20,800 underlying)
  • Other

    Class B Warrants (right to buy)

    2017-11-29+20,80020,800 total(indirect: By LLC)
    Exercise: $0.38From: 2017-11-29Exp: 2018-05-07Common Stock (20,800 underlying)
  • Other

    Common Stock

    2017-11-29+15,099,08324,000,000 total(indirect: By Intiva USA Inc.)
  • Other

    Common Stock

    2017-11-29+1,258,2572,000,000 total
  • Other

    Class A Warrants (right to buy)

    2017-11-29+20,80020,800 total(indirect: By LLC)
    Exercise: $0.25From: 2017-11-29Exp: 2018-01-31Common Stock (20,800 underlying)
Footnotes (7)
  • [F1]As adjusted to reflect a one-for-six reverse split of the issuer's common stock effective November 29, 2017
  • [F2]Acquired in exchange for all of Intiva USA's shares of Intiva BioPharma Inc.
  • [F3]Acquired in exchange for all of Jeffrey Friedland's shares of Intiva BioPharma Inc.
  • [F4]Acquired in exchange for all of Lane 6552 LLC's shares of Intiva BioPharma Inc.
  • [F5]Acquired in exchange for all of Lane 6552 LLC's Class A warrants of Intiva BioPharma Inc.
  • [F6]Acquired in exchange for all of Lane 6552 LLC's Class B warrants of Intiva BioPharma Inc.
  • [F7]Acquired in exchange for all of Lane 6552 LLC's Class C warrants of Intiva BioPharma Inc.

Documents

1 file
  • 4
    marketforms-40370.xmlPrimary

    PRIMARY DOCUMENT